ULB

Cancer Epigenetics & Epigenomics are coming of Age

Dr. Jana Jeschke
Laboratory of Cancer Epigenetics
Directed by **Prof. François Fuks**
Faculty of Medicine (Campus Erasme) at ULB

I. Epigenetics: Essential Notions



II. Epigenetics & Cancers

III. Epigenomics is coming of age (technologies)

IV. Applications/ Translational Cancer Epigenomics

V. New Epigenetics field



I. Epigenetics: Essential Notions

Notions of Epigenetics

Genetic= Cellular manual

inrecentyearsepigeneticalterationshavecome toprominenceincancerresearchinparticularhy permethylationofcpgislandslocatedintheprom oterregionsoftumorsuppressorgenesisnowfirm lyestablishedasanimportantmechanismforgene inactivationincanceroneofthemostremarkable achievementsinthefieldhasbeentheidentifica tionofthemethylcpgbindingdomainfamilyofpro teinswhichprovidemechanisticlinksbetweensp ecificpatternsofdnamethylationandhistonemo difications

Epigenetic= how to read the manual

In recent years, epigenetic alterations have come to prominence in cancer research. In particular, hypermethylation of CpG islands located in the promoter regions of tumor-suppressor genes is now firmly established as an important mechanism for gene inactivation in cancer. One of the most remarkable achievements in the field has been the identification of the methyl-CpG-binding domain family of proteins, which provide mechanistic links between specific patterns of DNA methylation and histone modifications.

Woman without her man is nothing

Woman, without her, man is nothing

Punctuation is important!!!

Definitions of Epigenetics

A NEW FRONTIER!

GENETICS

(ADN)



Genetic Code

→ ***4 letters/ nucleotides (ATGC)***

Dressing of our chromosomes/genes: by epigenetics

EPIGENETICS

(chromosome)



→



→ ***5^{e} letter/ nucleotide (5mC)***

Definitions of Epigenetics

Aristotle, 384-322 BC:

"… Epigenesis … development of individual organic form from unformed"



Conrad Waddington, 1942:

"… is the branch of biology which studies the causal interactions between genes and their products, which bring the phenotype into being"

Arthur Riggs, 1996:

"…is the study of mitotically and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA sequence"

Definitions of Epigenetics

More recently, Denise Barlow (Vienna):

"… Epigenetics has always been all the weird and wonderful things that cannot be explained by genetics"

✓ Not DNA Sequence („epi")

✓ Heritable

✓ Influence Gene Function

Influence of our environment/life style



Influence of our environment/life style



Influence of our environment/life style

Lamarckism's revival…



Influence of our environment/life style

Why identical twins are not the same?

EPIGENETICS

Identical twins: epigenetics makes the difference

Influence of our environment/life style

PNAS

Epigenetic differences arise during the lifetime of monozygotic twins

Mario F. Fraga*, Esteban Ballestar*, Maria F. Paz*, Santiago Ropero*, Fernando Setien*, Maria L. Ballestar†, Damia Heine-Suñer‡, Juan C. Cigudosa§, Miguel Urioste¶, Javier Benitez¶, Manuel Boix-Chornet†, Abel Sanchez-Aguilera†, Charlotte Ling‖, Emma Carlsson‖, Pernille Poulsen**, Allan Vaag**, Zarko Stephan††, Tim D. Spector††, Yue-Zhong Wu‡‡, Christoph Plass‡‡, and Manel Esteller*§§

*Epigenetics, §Cytogenetics, and ¶Genetic Laboratories, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain; †Department of Behavioral Science, University of Valencia, 46010 Valencia, Spain; ‡Molecular Genetics Laboratory, Genetics Department, Son Dureta Hospital, 07014 Palma de Mallorca, Spain; ‖Department of Clinical Sciences, University Hospital Malmö, Lund University, S-205 02 Malmö, Sweden; **Steno Diabetes Center, 2820 Gentofte, Denmark; ††Twin Research and Genetic Epidemiology Unit, St. Thomas' Hospital, London SE1 7EH, United Kingdom; and ‡‡Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210





Influence of our environment/life style

Diet

Research Article
For reprint orders, please contact: reprints@futuremedicine.com
Epigenomics
Tobacco smoking-associated genome-wide DNA methylation changes in the EPIC study

Cigaret

Disease exposure

REVIEW
Epigenetic changes in virus-associated human cancers
Hsin Pai LI[1], Yu Wei LEU[2],Yu Sun CHANG[1]*
[1]Graduate Institute of Basic Medical Sciences, Chang Gung University, Kwei-shan, Taoyuan, Taiwan 333.
[2]Department of Life Science and Institute of Molecular Biology, ChungCheng University, Ming-Hsiung, Chia-Yi, Taiwan 621.

Epigenetics

Drug

…

Exercise

Neuropsychopharmacology (2010) 35, 2450–2461
© 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00
www.neuropsychopharmacology.org
DNA Methylation Regulates Cocaine-Induced Behavioral Sensitization in Mice
Kaili Anier[2], Kristina Malinovskaja[1], Anu Aonurm-Helm[1], Alexander Zharkovsky[1] and Anti Kalda*[,1]
[1]Department of Pharmacology, University of Tartu, Tartu, Estonia

26 • Exercise, Inflammation, and DNA Methylation
Exercise and inflammation-related epigenetic modifications: focus on DNA methylation
Steven Horsburgh[1], Paula Robson-Ansley[1,2], Rozanne Adams[2], Carine Smith[2]
[1] Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, United Kingdom.
[2] Department of Physiological Sciences, Stellenbosch University, South Africa

Influence of our environment/life style

nature Vol 456|6 November 2008

RESEARCH HIGHLIGHTS

Famine's shadow

Proc. Natl Acad. Sci. USA doi:10.1073/pnas.0806560105 (2008)

If a starving woman becomes pregnant, her child's DNA can still bear traces of her hunger more than six decades later.

Lambert Lumey of Columbia University in New York, Bastiaan Heijmans of Leiden University Medical Center in the Netherlands and their colleagues studied the methyl groups attached to a gene called *IFG2*. They measured methylation at five points along *IFG2* in people prenatally exposed to the 1944–45 Dutch famine — when a Nazi embargo led to food rationing in the west of Holland of fewer than 700 calories a day.

Compared with same-sex siblings conceived when the same mothers had more flesh on their bones, those affected early in fetal development have less methylation on *IFG2* today, implying that their cells express it more readily.

Early-life environmental conditions can cause epigenetic changes in humans that persist throughout life!



Central roles in biology and medicine

Central roles in biology and medicine

~80 000 genes

~15 000 genes

~20 000 genes

« We are more than the sum of our genes! »

While the average human-chimpanzee divergence is ~1% across the genome, at CpG sites it increases to ~15%

Central roles in biology and medicine

Our body=more than 250 cell types with the same genome





→ unique repertoire of gene expression



Central roles in biology and medicine

In Health

In Disaese



Epigenetic Actors



I. Chromatin

II. DNA modifications

III. Non coding RNAs

IV. Other?

Chromatin



In nucleus, chromatin compacts genome





Nucleosome: fundamental unit of chromatin (DNA + histones)

2.1 Chromatin



Euchromatin



Active genes transcribed

Heterochromatin



Silenced Genes, repressed

Chromatin



- Several degrees of chromatin compaction

- This compaction is DYNAMIC & influences gene expression:

OPEN chromatin → genes ON

CLOSED chromatin → genes OFF

Chromatin

⇩

regulated by epigenetic modifications

⇩

"chromatin modifying enzymes"

Chromatin

Increasing epigenetics complexity

1. First layer/modification

(1996)



2. Multitude of modifications



3. Interconnections/Interdependancies



4. COMBINATIONS determine gene expression



Chromatin

Increasing epigenetics complexity

5. Mono,di,tri-methylation *(2003)*



6. New modifications *(2004-2008,…)*



GENE EXPRESSION / EXTEND INFORMATION

HISTONE CODE

HOW TO PREDICT HISTONE COMBINATION AND GENE EXPRESSION OUTPUT/BIOLOGICAL CONSEQUENCES?

Chromatin

Enzymes modifying chromatine



- Associated with gene activation and/or repression

- **INTERPLAY** between these chromatin associated modifications

Chromatin



Activation

H3K4me3

H4K16ac

H4K9ac

Repression

H3K9me3

H3K27me3



DNA modifications

DNA methylation

Major features:



- CG dinucleotides
- only DNA modification known untill 2009 (hmC, fC, CaC,…)

DNA methylation

- Not random

  - CpGs under represented (prediction)
  - mCpG high mutagenic potential (thymine)



- CpG island

  - CG rich (>50% C+G), 500 to 2000 bp, in promoters
  - NOT METHYLATED





DNA methylation

- Gene silencing





Promoters

Gene bodies: Role in activation and elongation

DNA methylation

Proteins implicated in DNA methylation

Readers

MBD

Methylated Binding Domain

Writers



DNMT

DNA methyltransferases



Erasers

TETs



DNA methylation

Writers

DNA methyltransferases (DNMTs)

***de novo* DNA Methyltransferase: Dnmt3a/3b**

Establisment of new methylation profile



DNA Methyltransferase of Maintenance: Dnmt1

"copy" of DNA methylation during DNA replication

Targeting of DNA methylation

Non random



How are these ESTABLISHED?

Targeting of DNA methylation

By Interaction with transcriptional factors



e.g. PML/RAR in leukemia *(Di Croce et al., **Science**)*

Myc in various cancers *(Brenner et al., **EMBO J.**)*

Repression by DNA methylation

By connection with other repressive machineries



The DNMT KMT connection

chromatin



GENE locked

(double security, double locking)

nature LETTERS

The Polycomb group protein EZH2 directly controls DNA methylation

Emmanuelle Viré[1], Carmen Brenner[1], Rachel Deplus[1], Loïc Blanchon[1], Mario Fraga[2], Céline Didelot[1], Lluis Morey[3], Aleyde Van Eynde[4], David Bernard[1], Jean-Marie Vanderwinden[5], Mathieu Bollen[4], Manel Esteller[2], Luciano Di Croce[3], Yvan de Launoit[1,6] & François Fuks[1]

II. Epigenetics & Cancer

Cancers: Genetics AND Epigenetics



(Knudson hypothesis)

Healthy Epigenetics

Normal *Healthy*



Altered Epigenetics

Aberrant *Cancer*



Epigenetics in cancer



Epigenetics in cancer

In ALL cancers: aberrant DNA methylation profiles

•Hypomethylation of silencing genes (repetitive sequences, pluripotent genes,…)

Chromosomic instability
Activation of forbiden genes

Transcription factors
Growth factors

•Hypermethylation of tumor suppressor genes

Repression of « control » genes

Control of cell cycle: p21,…
Control of apoptosis: p53…
Control of DNA repair: MGMT…

Epigenetics in cancer

All Cancers:

- Silencing of tumor suppressor genes: e.g. Rb, p16, RARb, MGMT
- Some specific of one cancer, others in many cancers



Epigenetics in cancer:

Increasing clinical implications



DIAGNOSTIC

- tumors at early stage
- molecular classification of tumors
- likely reaction to treatment

Epigenetics in cancer:

Cancers: Detection in fluids

Disease	DNA source	Markers
Bladder cancer	Plasma	*CDKN2A* (*ARF*)
	Plasma	*CDKN2A* (*INK4A*)
	Serum	*CDKN2A* (*INK4A*)
Breast cancer	Plasma	*CDKN2A* (*INK4A*)
	Plasma	*CDKN2A* (*INK4A*)
Colorectal cancer	Serum	*MLH1*
	Serum	*CDKN2A* (*INK4A*)
	Serum	*CDKN2A* (*INK4A*)
	Plasma	*CDKN2A* (*INK4A*)
Oesophageal cancer	Plasma (AC)	*APC*
	Plasma (SCC)	*APC*
	Serum (SCC)	*CDKN2A* (*INK4A*)
Gastric cancer	Serum	*CDH1*
	Serum	*CDKN2A* (*INK4A*)
	Serum	*CDKN2B* (*INK4B*)
	Serum	*DAPK1*
	Serum	*GSTP1*
	Serum	Panel of five
Head and neck cancer	Serum	*CDKN2A* (*INK4A*)
	Serum	*DAPK1*
	Serum	*MGMT*
	Serum	Panel of three
	Plasma (nasopharyngeal)	*DAPK1*
Liver cancer	Plasma/serum	*CDKN2A* (*INK4A*)
	Plasma/serum	*CDKN2B* (*INK4B*)
	Plasma/serum	Panel of two
Lung cancer	Serum (NSCLC)	*CDKN2A* (*INK4A*)
	Serum (NSCLC)	*DAPK1*
	Serum (NSCLC)	*GSTP1*
	Serum (NSCLC)	*MGMT*
	Serum (NSCLC)	Panel of four
	Plasma	*CDKN2A* (*INK4A*)
	Plasma/serum	*APC*
	Plasma	*CDKN2A* (*INK4A*)
	Plasma (NSCLC)	*CDKN2A* (*INK4A*)
Prostate cancer	Plasma/serum	*GSTP1*
	Plasma	*GSTP1*

Epigenetics in cancer:

Commercially-available DNA methylation test kits for cancer

Gene(s)	Type of Biomarker	Type of Cancer	Diagnostic Test Kit: Brand Name (Manufacturer)	References
VIM	diagnostic	Colorectal	Cologuard (Exact Sciences)	[128] [1]
SEPT9	diagnostic	Colorectal	Epi proColon (Epigenomics) ColoVantage (Quest Diagnostics) RealTime mS9 (Abbott)	[129] [1]
SHOX2	diagnostic	Lung	Epi prolong (Epigenomics)	[130–135] [2]
GSTP1/APC/RASSF1A	diagnostic	Prostate	ConfirmMDx (MDx Health)	[136–138] [1]
MGMT	predictive	Glioblastoma	PredictMDx Glioblastoma (MDx Health) SALSA MS-MLPA probemix ME011 Mismatch Repair genes (MRC-Holland) PyroMark MGMT Kit (Qiagen)	[121,139,140] [1]

Epigenetic Cancer Therapy

Strategy: DNA methylation-histone modifications



Epigenetic Cancer Therapy

Table 1 Selected Epigenetic Drugs

Drug	Compound	Study Phase
DNMT inhibitors	Azacitidine (Vidaza)	US FDA–approved in MDS
	Decitabine (Dacogen)	US FDA–approved in MDS
	S110	Phase I
	CP-4200 (elaidic azacytidine)	Preclinical
	Nanaomycin A	Preclinical
HDAC inhibitors	Vorinostat (Zolinza)	US FDA–approved in CTCL
	Romidepsin (Istodax)	US FDA–approved in CTCL
	Panobinostat	Phase II
	Belinostat	Phase I/II
	Valproic acid	Phase II
	Belinostat	Phase II/III
HMT inhibitors	Deazaneoplanocin A (DZNep)	Preclinical
	Quinazoline derivatives	Preclinical
	Ellagic Acid	Preclinical
Histone demethylase inhibitors	Polyamine analogues	Preclinical
	Hydroxamate analogues	Preclinical
HAT inhibitors	Spermidinyl-CoA derivatives	Preclinical
	Hydrazinocurcumin	Preclinical
	Pyrazolone-containing small molecules	Preclinical

Epigenetic Cancer Therapy

Zebularine, a new DNA demethylating agent effective against murine lymphoma











Epigenetic Cancer Therapy

Already a reality!

Leukemia: Myelodysplasie (MDS)



Bone marrow in a person with MDS



Healthy bone marrow

Rather in « older » men (60-70 years)

Treatment with azacytidine
DNMT inhibitor

Epigenetic Cancer Therapy

Use of combined epigenetic drugs

Application in anti-cancer therapy of DNMT-HDAC connexion



Published in final edited form as:
Semin Hematol. 2008 January ; 45(1): 23–30.

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

Elizabeth A. Griffiths, MD and

Published in final edited form as:
Future Oncol. 2011 February ; 7(2): 263–283. doi:10.2217/fon.11.2.

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

K Ted Thurn[1,*], **Scott Thomas**[1,*], **Amy Moore**[1,*], and **Pamela N Munster**[†,1]
[1]Department of Medicine, Hematology/Oncology Division. University of California, San Francisco, CA, USA

III. Epigenomics is coming of age

Why of interest?

Sequencing the human genome:







"Is that all?"

Epigenomics

nature

Time for the epigenome

The complexity of genetic regulation is one of the great wonders of nature, but it represents a daunting challenge to unravel. The International Human Epigenome Consortium is an appropriate response.



Epigenomics

Epigenetics: study of epigenetic modifications of a specific gene

Epigenomics: study of epigenetic modifications of all the genome

Not ONE but MANY EPIGENOMES



Inter- and intra-individual differences

NGS & Cancer Epigenomics: A « BIG SURPRISE »

When Genetics meets Epigenetics



Cancer mutations: increasing number in epigenetic genes

Epigenomics notions

Data Before GA

Genbank 2005 – 50 Gb



Epigenomics notions

Massive Increase in Data with the Entry of the GA

Epigenomics notions

Estimated Throughput in 2009 From all the GA's



Epigenomic technologies

DNA methylome: various technologies



Epigenomic technologies

DNA methylome: various technologies

Pretreatmen		
	Array-based analysis	**NGS-based analysis**
Enzyme digestion	• DMH • MCAM • HELP • MethylScope • CHARM • MMASS	• Methyl–seq • MCA–seq • HELP–seq • MSCC
Affinity enrichment	• MeDIP • mDIP • mCIP • MIRA	• MeDIP–seq • MIRA–seq
Sodium bisulphite	• BiMP • GoldenGate • Infinium	• RRBS • BC–seq • BSPP • WGSBS

Infinium technologies

- Many clinical samples:



- Fast

- Reproducible

- Moderate cost

- Low amount of genomic DNA

- DNA methylation and gene expression



Epigenomic notions

Epigenomic technologies

Histone marks profiling: ChIP-Seq



ULB

ULB Epigenomics core facility/EPICS

(Head: F. Fuks)

(e.g. DNA methylome, ChIP-Seq, RNA-Seq)

nature

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

*(Boumahdi, …, Fuks & Blanpain, **Nature, 2014**)*

IV. Applications / Translational Cancer Epigenomics

Epigenomic and breast Cancers

EMBO
Molecular Medicine

Research Article
Epigenetic portraits of human breast cancers

DNA methylation profiling reveals a predominant immune component in breast cancers

*Sarah Dedeurwaerder[1†], Christine Desmedt[2†], Emilie Calonne[1], Sandeep K. Singhal[2], Benjamin Haibe-Kains[2,3], Matthieu Defrance[1], Stefan Michiels[2], Michael Volkmar[1], Rachel Deplus[1], Judith Luciani[1], Françoise Lallemand[2], Denis Larsimont[4], Jérôme Toussaint[2], Sandy Haussy[2], Françoise Rothé[2], Ghizlane Rouas[2], Otto Metzger[2], Samira Majjaj[2], Kamal Saini[2], Pascale Putmans[1], Gérald Hames[5], Nicolas van Baren[6], Pierre G. Coulie[5], Martine Piccart[7], Christos Sotiriou[2**†], François Fuks[1*†]*

What is the contribution of the DNA methylome to the complexity of the breast cancer?

Epigenomic and breast Cancers



Worldwide: 1.400.000 new cases / 500.000 deaths
EU-25: 350.000 new cases / 130.000 deaths

- **1/9 women**
- **Death of 1/3 women with breast cancer**

Epigenomic and breast Cancers

Breast cancers = « several diseases »



Women with similar clinico-pathological characteristics can have very different clinical outcome



Metastasis

Critical need of additional biomarkers



THERAPEUTIC DECISIONs:

How to classify breast cancers



Mortality:

Histological Grade



Grade 1
20%

Low Mortality

Grade 2
60%

Intermediate

Grade 3
20%

High

How to classify breast cancers

Gene expression *(microarray)*





4 «expression subtypes»

Epigenomic and breast Cancers



EMBO
Molecular Medicine

Research Article
Epigenetic portraits of human breast cancers

DNA methylation profiling reveals a predominant immune component in breast cancers

*Sarah Dedeurwaerder[1†], Christine Desmedt[2†], Emilie Calonne[1], Sandeep K. Singhal[2], Benjamin Haibe-Kains[2,3], Matthieu Defrance[1], Stefan Michiels[2], Michael Volkmar[1], Rachel Deplus[1], Judith Luciani[1], Françoise Lallemand[2], Denis Larsimont[4], Jérôme Toussaint[2], Sandy Haussy[2], Françoise Rothé[2], Ghizlane Rouas[2], Otto Metzger[2], Samira Majjaj[2], Kamal Saini[2], Pascale Putmans[1], Gérald Hames[5], Nicolas van Baren[6], Pierre G. Coulie[5], Martine Piccart[7], Christos Sotiriou[2**†], François Fuks[1*†]*

What is the contribution of the DNA methylome to the complexity of the breast cancer?

a

248 tissue samples

Infinium Methylation 27

MAIN SET OF PATIENTS:
123 breast tissues



(VALIDATION SET OF PATIENTS:
125 breast tissues)

Epigenomic and breast Cancers



Six methylation groups of breast tumours

- **3 known expression subtypes:** 2 ≈ HER2 ; 3 ≈ Basal-like ; 6 ≈ Luminal A
- **3 NEW subtypes:** 1, 4 and 5

Similar data in independent validation set (125 samples)

Epigenomic and breast Cancers

1. New subgroups

Transcriptome



DNA methylome



Refining tumor ***taxonomy***

2. Immune component

Highlight cell type composition of the tumor
Lymphocyte infiltration
microenvironment

Key contribution of DNA methylome to the complexity of breast cancer

PERSPECTIVES

new Biomarkers

Therapeutic Pronostics

New therapies (epigenetics)

Towards a personalized treatment of breast cancers



Perspectives on DNA methylation

Perspectives on DNA methylation

1. DNA methylome: not just for cancers

Type 2 Diabetes



The EMBO Journal (2012) 31, 1405–1426 | © 2012 European Molecular Biology Organization | Some Rights Reserved 0261-4189/12
www.embojournal.org

THE EMBO JOURNAL

EMBO open

DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients

Michael Volkmar[1], Sarah Dedeurwaerder[1], Daniel A Cunha[2], 'Matladi N Ndlovu[1], Matthieu Defrance[1], Rachel Deplus[1], Emilie Calonne[1], Ute Volkmar[3], Mariana Igoillo-Esteve[2], Najib Naamane[2], Silvia Del Guerra[4], Matilde Masini[4], Marco Bugliani[4], Piero Marchetti[4], Miriam Cnop[2,5], Decio L Eizirik[2] and François Fuks[1,*]

Introduction

Type 2 diabetes (T2D) has developed into a major public health concern. While previously considered as a problem primarily for western populations, the disease is rapidly gaining global importance, as today around 285 million people are affected worldwide (IDF, 2009). Lifestyle and behavioural factors play an important role in determining T2D risk. For example, experimentally induced intrauterine growth retardation as well as nutrient restriction during

Neurological disaese



REVIEW

nature medicine

Epigenetic mechanisms in neurological disease

Mira Jakovcevski & Schahram Akbarian

Perspectives on DNA methylation

2. Methylation changes also outside promoters



Promoter **Non-Promoter** (Gene body/Intergenic)



Known Promoter changes

‘Outside’ Promoter changes

Did we MISS many key methylation alterations?

More differential methylation in non-promoter regions



Promoter **Non-Promoter** (Gene body/Intergenic)

Differential Methylation:



Improved Infinium technology



As part of Illumina Consortium:
Infinium Methylation 2.0
(from 27K to 450K)

Evaluation + New Bioinformatic Tool:

TECHNOLOGY REPORT

For reprint orders, please contact: reprints@futuremedicine.com

Evaluation of the Infinium Methylation 450K technology

KEYWORDS: bisulfite-based method DNA methylation DNA methylome epigenetics epigenomics Infinium I Infinium II Infinium Methylation 450K peak-based correction

Sarah Dedeurwaerder[1‡], Matthieu Defrance[1‡], Emilie Calonne[1], Hélène Denis[1], Christos Sotiriou[2] & François Fuks*[1]

DNA methylation of cytosine residues is essential to the normal development and maintenance of gene-expression patterns [1]. In humans, it

Such alterations of DNA methylation in both cancer and other diseases have raised wide interest in developing large-scale DNA

DNA methylation: beyond CpG islands and repression

Better Breast Cancer Classification?

Martin Bizet



2 NEW BASAL subtypes: 1 and 2

DNA methylation outside promoters refine tumor classification

Perspectives on DNA methylation

3. « new » DNA modifications



ELUSIVE DNA DEMETHYLASE???

TETs and hydroxymethylation



TETs functions: In Health

Development



Cell pluripotency



Neurogenesis



nature COMMUNICATIONS

ARTICLE

Received 1 Oct 2010 | Accepted 16 Feb 2011 | Published 15 Mar 2011 DOI: 10.1038/ncomms1240

5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming

Mark Wossidlo[1], Toshinobu Nakamura[2], Konstantin Lepikhov[1], C. Joana Marques[3], Valeri Zakhartchenko[4], Michele Boiani[5], Julia Arand[1], Toru Nakano[2], Wolf Reik[3,6] & Jörn Walter[1]

LETTER

doi:10.1038/nature10443

The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes

Tian-Peng Gu[1]*, Fan Guo[1]*, Hui Yang[2]*, Hai-Ping Wu[1]†, Gui-Fang Xu[1], Wei Liu[1], Zhi-Guo Xie[1], Linyu Shi[2], Xinyi He[3], Seung-gi Jin[4], Khursheed Iqbal[5], Yujiang Geno Shi[4], Zixin Deng[2], Piroska E. Szabó[5], Gerd P. Pfeifer[4], Jinsong Li[2] & Guo-Liang Xu[1]

Sperm and eggs carry distinctive epigenetic modifications that are adjusted by reprogramming after fertilization[1]. The paternal genome in a zygote undergoes active DNA demethylation before the first mitosis[2,3]. The biological significance and mechanisms of this paternal epigenome remodelling have remained unclear[4]. Here we report that, within mouse zygotes, oxidation of 5-methylcytosine

To study the biological function of Tet3 in mouse, we generated a conditional knockout allele abolishing its catalytic activity (Supplementary Fig. 6a). Because homozygous mutation led to neonatal lethality, we achieved germ-line-specific deletion of Tet3 from primordial germ cells (PGCs) in [*Tet3*$^{f/-}$, TNAP-Cre] conditional knockout (CKO) mice.

Vol 466|26 August 2010|doi:10.1038/nature09303 nature

LETTERS

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

Shinsuke Ito[1,2], Ana C. D'Alessio[1,2], Olena V. Taranova[1,2], Kwonho Hong[1,2], Lawrence C. Sowers[3] & Yi Zhang[1,2]

DNA methylation is one of the best-characterized epigenetic modifications[1–4]. Although the enzymes that catalyse DNA methylation have been characterized, enzymes responsible for demethylation have been elusive[5]. A recent study indicates that the human TET1 protein could catalyse the conversion of 5-methylcytosine (5mC) of DNA to 5-hydroxymethylcytosine (5hmC), raising the

Supplementary Fig. 3b). Interestingly, whereas the enforced expression of Tet3 does not cause an obvious decrease in 5mC staining (Supplementary Fig. 2), it does result in the generation of 5hmC (Fig. 1a), indicating that Tet3 is indeed enzymatically active *in vivo*.

To evaluate the enzymatic activity *in vitro*, we purified Flag-tagged Tet catalytic domains as well as their corresponding catalytic mutants

LETTER

doi:10.1038/nature10008

Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation

Gabriella Ficz[1]*, Miguel R. Branco[1]*, Stefanie Seisenberger[1], Fátima Santos[1], Felix Krueger[2], Timothy A. Hore[1], C. Joana Marques[1]†, Simon Andrews[2] & Wolf Reik[1,3]

Methylation at the 5′ position of cytosine in DNA has important roles in genome function and is dynamically reprogrammed during early embryonic and germ cell development[1]. The mammalian genome also contains 5-hydroxymethylcytosine (5hmC), which seems to be generated by oxidation of 5-methylcytosine (5mC) by the TET family

By immunofluorescence we found strong nuclear staining for 5hmC in ES cells (and in other cell types) that broadly overlapped in euchromatic regions with staining for 5mC, whereas DAPI-dense heterochromatic regions are highly enriched for 5mC but not 5hmC (Fig. 1b and

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

Mamta Tahiliani,[1] Kian Peng Koh,[1] Yinghua Shen,[2] William A. Pastor,[1] Hozefa Bandukwala,[1] Yevgeny Brudno,[2] Suneet Agarwal,[3] Lakshminarayan M. Iyer,[4] David R. Liu,[2]* L. Aravind,[4]* Anjana Rao[1]*

DNA cytosine methylation is crucial for retrotransposon silencing and mammalian development. In a computational search for enzymes that could modify 5-methylcytosine (5mC), we identified TET proteins as mammalian homologs of the trypanosome proteins JBP1 and JBP2, which have been proposed to oxidize the 5-methyl group of thymine. We show here that TET1, a fusion partner of the MLL gene in acute myeloid leukemia, is a 2-oxoglutarate (2OG)– and Fe(II)-dependent enzyme that catalyzes conversion of 5mC to 5-hydroxymethylcytosine (hmC) in cultured cells and in vitro. hmC is present in the genome of mouse embryonic stem cells, and hmC levels decrease upon RNA interference–mediated depletion of TET1. Thus, TET proteins have potential roles in epigenetic regulation through modification of 5mC to hmC.

5-methylcytosine (5mC) is a minor base in found in repetitive DNA elements, suggesting essential for X-inactivation and asymmetric expression of imprinted genes (3). In somatic cells, promoter methylation often shows a correlation with gene expression: CpG methylation may directly interfere with the binding of certain transcriptional regulators to their cognate DNA sequences or may enable recruitment of methyl-CpG binding proteins that create a repressed chromatin environment (4). DNA methylation patterns are highly dysregulated in cancer: Changes in methylation status have been postulated to inactivate tumor suppressors and activate oncogenes, thus contributing to tumorigenesis (5).

[1]Department of Pathology, Harvard Medical School and Immune Disease Institute, 200 Longwood Avenue, Boston, MA 02115, USA. [2]Department of Chemistry and Chemical Biology and the Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA. [3]Division of Pediatric Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Boston, MA 02115, USA. [4]National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda,

Downloaded

REPORTS

The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain

Skirmantas Kriaucionis and Nathaniel Heintz*

Despite the importance of epigenetic regulation in neurological disorders, little is known about neuronal chromatin. Cerebellar Purkinje neurons have large and euchromatic nuclei, whereas granule cell nuclei are small and have a more typical heterochromatin distribution. While comparing the abundance of 5-methylcytosine in Purkinje and granule cell nuclei, we detected the presence of an unusual DNA nucleotide. Using thin-layer chromatography, high-pressure liquid chromatography, and mass spectrometry, we identified the nucleotide as 5-hydroxymethyl-2′-deoxycytidine (hmdC). hmdC constitutes 0.6% of total nucleotides in Purkinje cells, 0.2% in granule cells, and is not present in cancer cell lines. hmdC is a constituent of nuclear DNA that is highly abundant in the brain, suggesting a role in epigenetic control of neuronal function.

To investigate Purkinje and granule cell nuclei, we took advantage of the fact that Purkinje cell DNA and 0.23 ± 0.01% in granule cell DNA. We noticed that the actual increase in the

2C). MS collision-induced fragmentation of the hmdC corresponding fraction from synthetic DNA produced the same ions (fig. S4). Together, these data demonstrate the presence of hmC in mouse cerebellar DNA. We were unable to detect hmC in four different cell lines of mouse and human origin (fig. S5A). The distribution of hmC in mouse tissues displays the enrichment exclusively in the brain, with higher abundance in the cortex and brainstem (fig. S5B).

It is unlikely that the hmC that we observed in vivo is a product of DNA damage (5, 6). We did not observe any other DNA damage products such as 8-oxoguanine, a preferential target for oxidants (7), or thymidine glycol, which is produced in vitro by the oxidation of mC (6). In addition, hmC is more abundant in brain, but not in other metabolically active nonproliferating tissues (fig. S5B). Finally, contrary to what one would expect for oxidative DNA damage, we found no correla-

2012

PERSPECTIVES: TETs in Cancers

Leukemia



TET2 wt → Normal

TET2 mut → Myeloid neoplasm

LETTERS

nature genetics

Acquired mutations in *TET2* are common in myelodysplastic syndromes

Saskia M C Langemeijer[1,5], Roland P Kuiper[2,5], Marieke Berends[1], Ruth Knops[1], Mariam G Aslanyan[1], Marion Massop[1], Ellen Stevens-Linders[1], Patricia van Hoogen[1], Ad Geurts van Kessel[2], Reinier A P Raymakers[1], Eveline J Kamping[2], Gregor E Verhoef[3], Estelle Verburgh[3], Anne Hagemeijer[4], Peter Vandenberghe[4], Theo de Witte[1], Bert A van der Reijden[1] & Joop H Jansen[1]

Cell PRESS

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Cyril Quivoron,[1,2,3,14] Lucile Couronné,[1,2,3,14] Véronique Della Valle,[1,2,3,14] Cécile K. Lopez,[1,2,3] Isabelle Plo,[2,3,4] Orianne Wagner-Ballon,[4,5] Marcio Do Cruzeiro,[6] Francois Delhommeau,[4,7] Bertrand Arnulf,[8] Marc-Henri Stern,[9] Lucy Godley,[10] Paule Opolon,[3] Hervé Tilly,[11] Eric Solary,[2,3,4] Yannis Duffourd,[2] Philippe Dessen,[1,2,3] Hélène Merle-Beral,[12] Florence Nguyen-Khac,[13] Michaéla Fontenay,[12] William Vainchenker,[2,3,4] Christian Bastard,[11,13] Thomas Mercher,[1,2,3,15] and Olivier A. Bernard[1,2,3,15,*]

Cell PRESS

***Tet2* Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation**

Kelly Moran-Crusio,[1,2,11] Linsey Reavie,[1,2,11] Alan Shih,[3,4,11] Omar Abdel-Wahab,[3,4] Delphine Ndiaye-Lobry,[1,2] Camille Lobry,[1,2] Maria E. Figueroa,[5] Apama Vasanthakumar,[6] Jay Patel,[3] Xinyang Zhao,[7] Fabiana Pema,[7] Suveg Pandey,[3] Jozef Madzo,[6] Chunxiao Song,[8] Qing Dai,[8] Chuan He,[8] Sherif Ibrahim,[1] Miloslav Beran,[9] Jiri Zavadil,[10] Stephen D. Nimer,[4,7] Ari Melnick,[5] Lucy A. Godley,[8] Iannis Aifantis,[1,2,11,*] and Ross L. Levine[3,4,11,*]
[1]Department of Pathology and NYU Cancer Institute

Melanoma



Cell

Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma

Christine Guo Lian,[1,2,13] Yufei Xu,[1,13] Craig Ceol,[3,6] Feizhen Wu,[3] Allison Larson,[3] Karen Dresser,[3] Wenqi Xu,[3] Li Tan,[3] Yeguang Hu,[1] Qian Zhan,[2] Chung-wei Lee,[3] Di Hu,[1] Bill Q. Lian,[1,8] Sonja Kleffel,[3] Yijun Yang,[10] James Neiswender,[6] Abraham J. Khorasani,[1] Rui Fang,[1] Cecilia Lezcano,[2] Lyn M. Duncan,[4] Richard A. Scolyer,[11] John F. Thompson,[11] Hojabr Kakavand,[11] Yariv Houvras,[3,12] Leonard I. Zon,[3] Martin C. Mihm Jr.,[5] Ursula B. Kaiser,[1] Tobias Schatton,[5] Bruce A. Woda,[7] George F. Murphy,[2,*] and Yujiang G. Shi[1,9,*]
[1]Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital
[2]Division of Dermatopathology, Department of Pathology, Brigham and Women's Hospital
[3]Stem Cell Program and Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Harvard Stem Cell Institute
[4]Division of Dermatopathology, Department of Pathology, Massachusetts General Hospital
[5]Department of Dermatology, Brigham and Women's Hospital
Harvard Medical School, Boston, MA 02115, USA

How do TETs work?

Searching for TETs interactors

by Proteomics:

- **First TET2/TET3 partners**
- **OGT is the strongest TET2 and TET3 interactor**

TETs and hydroxymethylation

TET2/3 interact with OGT and increase its activity



TET2/3 colocalize with OGT (influencing H3K4me3/ transcriptional activation)

In Tet2 KO: decreased GlcNAc and H3K4me3



- **TET2/3 control GlcNAcylation through association with OGT**
- **A mechanism for TET-mediated transcriptional activation**

New Epigenomic Technology

Our Illumina Plateforme :

Hydroxymethylation – Next Gen Sequencing (*hmC-Seq*)

TETs functions: In Cancers



Cancer Cell



HALLMARK OF CANCERS?

How, Why, When, Where?

DNA Hydroxymethylation/hmC:
HALLMARK OF CANCERS



Mechanisms &
Clinical relevance:
current key challenge

1. Mechanistic side

2. Translational side



V. A new epigenetics field



RNA modifications

Growing catalogue of RNA modifications: over 100



m^6A



Pseudo U

• • •



m^7G



t^6A



Ac^6A

LETTER

doi:10.1038/nature12730

N^6-methyladenosine-dependent regulation of messenger RNA stability

Xiao Wang[1], Zhike Lu[1], Adrian Gomez[1], Gary C. Hon[2], Yanan Yue[1], Dali Han[1], Ye Fu[1], Marc Parisien[3], Qing Dai[1], Guifang Jia[1,4], Bing Ren[2], Tao Pan[3] & Chuan He[1]

LETTER

doi:10.1038/nature13802

Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells

Thomas M. Carlile[1], Maria F. Rojas-Duran[1], Boris Zinshteyn[1], Hakyung Shin[1], Kristen M. Bartoli[1] & Wendy V. Gilbert[1]

Cell

Article

N^6-methyladenosine Modulates Messenger RNA Translation Efficiency

Xiao Wang,[1,2,4] Boxuan Simen Zhao,[1,2,4] Ian A. Roundtree,[2,3] Zhike Lu,[1,2] Dali Han,[1,2] Honghui Ma,[1,2] Xiaocheng Weng,[1,2] Kai Chen,[1,2] Hailing Shi,[1,2] and Chuan He[1,2,3,*]
[1]Department of Chemistry and Institute for Biophysical Dynamics
[2]Howard Hughes Medical Institute

m^{6}A RNA methylation



Post-transcriptional regulation!

m^{6}A RNA methylation

Development



Molecular Cell

The RNA m^{6}A Reader
Post-transcriptional R
Transcriptome and Oc

LETTER

doi:10.1038/nature21355

m^{6}A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition

Boxuan Simen Zhao[1,2*], Xiao Wang[1,2*], Alana V. Beadell[3*], Zhike Lu[1,2], Hailing Shi[1,2], Adam Kuuspalu[3], Robert K. Ho[3] & Chuan He[1,2,4]

Cell pluripotency



Published in final edited form as:
Cell Stem Cell. 2014 December 4; 15(6): 707–719. doi:10.1016/j.stem.2014.09.019.

m^{6}A RNA modification controls ce
embryonic stem cells

Pedro J Batista[1,*], Benoit Molinie[2,*], Jinkai Wang
Donna M Bouley[4], Ernesto Lujan[5,6], Bahareh Ha
Ryan A Flynn[1], Chan Zhou[2], Kok-Seong Lim[7], P
Mullen[2,8], Yi Xing[3,¶], Cosmas C Giallourakis[2,8,¶]

Published in final edited form as:
Cell Stem Cell. 2014 December 4; 15(6): 707–719. doi:10.1016/j.stem.2014.09.019.

m^{6}A RNA modification controls cell fate transition in mammalian embryonic stem cells

Pedro J Batista[1,*], Benoit Molinie[2,*], Jinkai Wang[3,*], Kun Qu[1], Jiajing Zhang[1], Lingjie Li[1], Donna M Bouley[4], Ernesto Lujan[5,6], Bahareh Haddad[5], Kaveh Daneshvar[2], Ava C Carter[1], Ryan A Flynn[1], Chan Zhou[2], Kok-Seong Lim[7], Peter Dedon[7], Marius Wernig[5], Alan C Mullen[2,8], Yi Xing[3,¶], Cosmas C Giallourakis[2,8,¶], and Howard Y Chang[1,¶]

Cancer



Cancer Cell

FTO Plays an Oncogenic Ro
Leukemia as a *N*^{6}-Methylad
Demethylase

Article

Cell Reports

Article

m^{6}A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells

Graphical Abstract

Authors

Qi Cui, Hailing Shi, Peng Ye, ..., Arthur D.



hmC in RNA?

Role of TETs?

Which model system?

Function/ Biology

Mammals



DNA



RNA

More simple model System:



RNA



Drosophila

Transcriptome-wide distribution of hmC RNA: hMeRIP-Seq in S2 cells

- Adapted from **MeRIP-Seq** for m6A

- **hMeRIP-Seq:H**ydroxy**ME**thylated **R**NA **I**mmuno**P**recipitation followed by **Seq**uencing using hmC antibody

Resource

Cell

Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons

Kate D. Meyer,[1] Yogesh Saletore,[2,3] Paul Zumbo,[2,3] Olivier Elemento,[2,3] Christopher E. Mason,[2,3,*] and Samie R. Jaffrey[1,*]
[1]Department of Pharmacology
[2]Department of Physiology and Biophysics

ARTICLE

doi:10.1038/nature11112

Topology of the human and mouse m^{6}A RNA methylomes revealed by m^{6}A-seq

Dan Dominissini[1,2]*, Sharon Moshitch-Moshkovitz[1]*, Schraga Schwartz[3]*†, Mali Salmon-Divon[1], Lior Ungar[2,4], Sivan Osenberg[1,2], Karen Cesarkas[1], Jasmine Jacob-Hirsch[1], Ninette Amariglio[1], Martin Kupiec[4], Rotem Sorek[3] & Gideon Rechavi[1,2]



BPM represents reads per base, per million mapped
permission, from REF 5 © (2012) Elsevier.

hMeRIP-Seq in S2 cells

hmC enriched targets

	Peaks	Transcripts
hMeRIP-Seq	3,058	1,597

Example: hmC-Seq peaks



Top hmC-targets

Gene Symbol	Chr	Enrichment Score
ph-d	chrX	323
CR43334	chr3L	322
gw	chr4	322
SRm160	chr3L	321
nocte	chrX	321
Bruce	chr3R	317
Droj2	chr3R	316

Gene Symbol	Chr	Enrichment Score
CR40572	chrU	314
kay	chr3R	312
Caf1-180	chrX	312
Gug	chr3L	312
spen	chr2L	310
kis	chr2L	310
chinmo	chr2L	310
CG9641	chr2L	310



hmC RNA is found within many transcripts

Localization of hmC RNA

hmC enriched targets by category



Motif for hmC regions



Non random distribution

UC-rich motif

Biology: dTet/hmC-RNA in fruitfly

dTet deficient flies: Phenotype?

(Ruth Steward)

RT-qPCR





†

Lethal Pupal stage

Genotype	Survival stage	% of escapers
dTet^{null}	Pupa	0

Morphological abnormalities in brain:

-Smaller brain
-Accumulation of neuroblasts
-Optic lobe and central brain disorganized

dTet essential for Drosophila development

Impaired brain development in dTet^{null}

CONCLUSIONS



S2 cells

dTet null flies

- **hmC-RNA enriched at polyA, by dTet**
- **hMeRIP-Seq: First picture of hmC-RNA**



- **Lethality at pupal stage**
- **Impaired brain development**
- **Accompanied with decreased hmC-RNA**

Role in mRNA translation:



RESEARCH | REPORTS

Science

RNA BIOCHEMISTRY

Transcriptome-wide distribution and function of RNA hydroxymethylcytosine

Benjamin Delatte,[1]*† Fei Wang,[2]* Long Vo Ngoc,[3]*‡ Evelyne Collignon,[1] Elise Bonvin,[1] Rachel Deplus,[1] Emilie Calonne,[1] Bouchra Hassabi,[1] Pascale Putmans,[1] Stephan Awe,[4]

Epigenetics



Laboratoire d'Epigénétique du Cancer
Faculté de Médecine (Campus Erasme)
ffuks@ulb.ac.be